AB0837 ITCH AS THE MAJOR MEDIATOR OF THE EFFECT OF TOFACITINIB ON HEALTH-RELATED QUALITY OF LIFE IN PsA: A MEDIATION ANALYSIS

Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient‐reported outcomes from a Phase 3 study

Jocelyne Papacharalambous

Journal of the European Academy of Dermatology and Venereology, 2016

Tofacitinib for the treatment of moderate to severe chronic plaque psoriasis in Japanese patients: Subgroup analyses from a randomized, placebo-controlled phase 3 trial

The Journal of dermatology, 2017

Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two, randomised, placebo-controlled, Phase 3 trials

Pedro Miranda

The British journal of dermatology, 2015

Do Patients and Physicians Agree in Their Assessment of the Severity of Psoriasis ? Insights from Tofacitinib Phase 3 Clinical Trials

Lotus Mallbris

2015

The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: A Phase 3, randomized, double-blind, placebo-controlled study

Tsen-fang Tsai

Journal of dermatological science, 2017

Effect of tofacitinib withdrawal and re-treatment on patient-reported outcomes: results from a Phase 3 study in patients with moderate to severe chronic plaque psoriasis

Mary Bachinsky

Journal of The European Academy of Dermatology and Venereology, 2016

Tofacitinib in psoriatic arthritis patients: skin signs and symptoms and health‐related quality of life from two randomized phase 3 studies

Journal of the European Academy of Dermatology and Venereology, 2020

A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis

British Journal of Dermatology, 2013

Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: A randomized phase 2 study

Mayte Suarez-Farinas

The Journal of allergy and clinical immunology, 2016

Tofacitinib for the treatment of moderate-to-severe psoriasis

Maria Sole Chimenti

Expert Review of Clinical Immunology, 2015

Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial

BMC dermatology, 2016

Effect of tofacitinib on dactylitis and patient-reported outcomes in patients with active psoriatic arthritis: post-hoc analysis of phase III studies

Ana-maria Orbai

BMC Rheumatology

A multi-item Physician Global Assessment scale to assess psoriasis disease severity: validation based on four phase III tofacitinib studies

Joseph Cappelleri

BMC Dermatology

Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial

Fernando Valenzuela

Lancet, 2015

Identifying and Quantifying the Role of Inflammation in Pain Reduction for Patients With Psoriatic Arthritis Treated With Tofacitinib: A Mediation Analysis

Rheumatology and Therapy

Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in phase 3 studies of tofacitinib

Oliver Fitzgerald

Arthritis Research & Therapy, 2021

Impact of Ixekizumab Treatment on Itch and Psoriasis Area and Severity Index in Patients with Moderate-to-Severe Plaque Psoriasis: An Integrated Analysis of Two Phase III Randomized Studies

Adam Reich

Dermatology and Therapy, 2018

Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial

Mary Bachinsky

British Journal of Dermatology, 2015

Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors

The New England journal of medicine, 2017

Dose Response and Pharmacokinetics of Tofacitinib (CP-690,550), an Oral Janus Kinase Inhibitor, in the Treatment of Chronic Plaque Psoriasis

CPT: Pharmacometrics & Systems Pharmacology, 2013

An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational Data

Huifeng Yun

Drug Safety, 2020

Median time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic arthritis treated with tofacitinib

Joseph Cappelleri

RMD Open, 2021

The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis

Peter Taylor

RMD Open

Tofacitinib in patients with moderate to severe chronic plaque psoriasis: 2-year efficacy and safety in an open-label long-term extension study

Tsen-fang Tsai

Journal of the American Academy of Dermatology, 2016

Efficacy and safety of tofacitinib by background methotrexate dose in psoriatic arthritis: post hoc exploratory analysis from two phase III trials

Clinical Rheumatology, 2021

Frequency and Duration of Early Non-serious Adverse Events in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with Tofacitinib

Rheumatology and Therapy, 2021

Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study

Oliver Fitzgerald

Rheumatology and therapy, 2020